Cargando…
Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Import...
Autores principales: | Kampa-Schittenhelm, Kerstin M., Vogel, Wichard, Bonzheim, Irina, Fend, Falko, Horger, Marius, Kanz, Lothar, Soekler, Martin, Schittenhelm, Marcus M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837740/ https://www.ncbi.nlm.nih.gov/pubmed/29545943 http://dx.doi.org/10.18632/oncotarget.24376 |
Ejemplares similares
-
Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
por: Kampa-Schittenhelm, K.M., et al.
Publicado: (2020) -
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017) -
ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
por: Rieger, Ingmar, et al.
Publicado: (2021) -
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2016) -
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
por: Tsintari, Vasileia, et al.
Publicado: (2022)